Phencyclidine (PCP) and Barbiturates
Phencyclidine (PCP), also known as "angel dust," is a dissociative anesthetic that alters perception, mood, and consciousness.
PCP primarily acts as an NMDA (N-methyl-D-aspartate) receptor antagonist. The NMDA receptor is a subtype of glutamate receptor, which plays a crucial role in synaptic plasticity, learning, and memory. By blocking these receptors, PCP disrupts normal glutamate signaling, leading to a disconnection between various parts of the brain and a significant alteration in consciousness. By inhibiting NMDA receptors, PCP reduces the excitatory effects of glutamate, leading to the "dissociative" effects that are characteristic of the drug. Users often report feeling detached from their bodies and reality, experiencing hallucinations, and having altered perceptions of time and space. PCP indirectly increases dopamine levels in the brain. This is thought to contribute to the drug's euphoric and reinforcing effects, as well as the potential for addiction. The surge in dopamine can also cause delusions, paranoia, and aggressive behavior. PCP also affects serotonin and norepinephrine pathways, although to a lesser extent than glutamate and dopamine. These interactions can contribute to mood changes, including anxiety, agitation, and depression.
Barbiturates are a class of drugs that act as central nervous system (CNS) depressants, widely used in the past for their sedative, anxiolytic (anti-anxiety), hypnotic (sleep-inducing), and anticonvulsant properties. However, due to their high potential for abuse, dependence, and overdose, they have largely been replaced by benzodiazepines and other safer drugs.
Barbiturates exert their effects primarily by enhancing the activity of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the CNS. They do this by binding to a specific site on the GABA-A receptor, distinct from the benzodiazepine binding site. This action increases the duration that the chloride ion channel remains open when GABA binds to the receptor, leading to greater inhibitory effects on neurons. By prolonging the opening of the chloride channels, barbiturates allow more chloride ions to flow into neurons. This hyperpolarizes the neuronal membrane, making it less likely to fire action potentials, thereby dampening neuronal excitability and leading to sedation, hypnosis, and anticonvulsant effects. At higher concentrations, barbiturates can directly activate the GABA\(_A\) receptor in the absence of GABA, which is one reason they are more dangerous than benzodiazepines. They can also inhibit excitatory neurotransmitter systems like glutamate and interfere with sodium and calcium channels, further depressing CNS activity.
Examples of Barbiturates
- Phenobarbital: Primarily used as an anticonvulsant to manage seizures, particularly in epilepsy. It is one of the longest-acting barbiturates.
- Pentobarbital: Used as a sedative-hypnotic and in veterinary medicine for euthanasia. In the past, it was used to treat insomnia or as a pre-anesthetic.
- Secobarbital: Once commonly used for treating insomnia and as a preoperative sedative, now it is rarely used due to the availability of safer alternatives.
- Thiopental (Pentothal): An ultra-short-acting barbiturate used primarily for the induction of anesthesia in surgical settings. It was historically known as a "truth serum" due to its disinhibitory effects at sub-anesthetic doses.
The combination of PCP and barbiturates is extremely dangerous and can lead to severe, often life-threatening, effects due to the synergistic impact on the CNS.
- Profound Sedation and Coma. Barbiturates are potent sedatives, and when used in conjunction with PCP, the level of sedation can become profound, leading to coma. PCP’s dissociative effects, combined with the sedative effects of barbiturates, can severely impair consciousness, making it difficult or impossible to awaken the person without medical intervention.
- Cardiovascular Collapse. PCP can cause increased heart rate and blood pressure, but when mixed with barbiturates, which lower blood pressure, the combined effects can lead to unpredictable cardiovascular outcomes. This can result in severe hypertension followed by sudden cardiovascular collapse, potentially leading to heart failure.
- Increased Risk of Overdose. The combination of these substances significantly heightens the risk of overdose. Both drugs lower the threshold for overdose when used together, meaning a dose that might be tolerable individually could become lethal when combined. Overdose symptoms include extreme confusion, hallucinations, seizures, respiratory arrest, and death.
- Exacerbation of Psychological Effects. PCP is notorious for causing severe psychological effects, including hallucinations, paranoia, and violent behavior. When barbiturates are added, the sedative effect might mask the user’s outward symptoms, but the underlying psychotic effects can be exacerbated. This can lead to unpredictable and potentially violent behavior as the user may be less aware of their surroundings while still experiencing intense hallucinations and paranoia.
- Impaired Judgment and Coordination. Both PCP and barbiturates impair motor skills and judgment. The combination can result in extreme dizziness, ataxia (loss of coordination), and impaired cognitive functions, increasing the risk of accidents and injuries.
- Seizures. PCP use, particularly at high doses or in combination with other substances like barbiturates, can lower the seizure threshold, leading to convulsions. These seizures can be difficult to control and may result in long-term neurological damage or death if not treated promptly.
- Potential for Long-term Neurological Damage. Chronic use of both substances, especially in combination, can lead to lasting neurological damage. This includes cognitive deficits, memory problems, and an increased risk of developing persistent psychosis or mood disorders.
All things considered, we recommend avoiding this combination under any conditions.
Last edited by a moderator: